Anti-Infective & Antiparasitic

Mebendazole Capsules — 100 mg

A 100 mg mebendazole capsule strength for selected intestinal worm infections.

Evidence brief in review

lennoxRXProduct image pending

Common goals: Mebendazole has established uses for selected intestinal worm infections.
Best program fit: Fits diagnosis-based antiparasitic care with organism-appropriate instructions, interaction review, and reinfection prevention guidance.
Format: Capsule · 100 mg

Partner education guide

Where this may fit in an offering.

Mebendazole has established uses for selected intestinal worm infections. A 100 mg capsule provides a defined unit strength when the formulation and prescription are verified. May fit a clinician-connected antiparasitic offering with testing and household guidance.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

Mebendazole has established uses for selected intestinal worm infections.
A 100 mg capsule provides a defined unit strength when the formulation and prescription are verified.
Diagnosis and reinfection prevention can support clear follow-up.

Program value

How it may support a program

May fit a clinician-connected antiparasitic offering with testing and household guidance.
Creates a natural checkpoint for metronidazole interaction, pregnancy, age, and liver-risk review.

The compounded capsule is not the approved chewable dosage form. Benefits are organism-specific and do not support viral, cancer, or general-wellness claims.

02 / Program fit

Program and operational considerations.

01Administration format: Catalog format: Capsule · 100 mg. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency: Frequency is individualized around the exact formulation, individual goals, tolerability, and monitoring plan.
03Expected duration: Course and repeat dosing depend on the diagnosed organism. Reinfection-prevention measures and contact management may be needed.
04Practical considerations: May fit a clinician-connected antiparasitic offering with testing and household guidance.

03 / Suitability considerations

Who may be considered.

Who may be considered

A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

May fit a clinician-connected antiparasitic offering with testing and household guidance.
Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

Common or temporary

Abdominal pain, diarrhea, gas, nausea, vomiting, reduced appetite, rash, or dizziness can occur.
Symptoms may depend on the infection and the duration of treatment.

Serious or important

Rare serious reactions include severe allergy, hepatitis or abnormal liver tests, neutropenia or agranulocytosis, seizures, and severe skin reactions.
Mebendazole should not be combined with metronidazole because Stevens-Johnson syndrome or toxic epidermal necrolysis has been reported.

Avoid or use only with specialist input

Use without a supported parasitic diagnosis, general wellness use, cancer treatment, viral-illness treatment, or an unverified compounded source.
Known mebendazole allergy, concurrent metronidazole, pregnancy without a clinician-led risk-benefit review, or use in children younger than two without specialist direction.

Screening checklist

Confirm the organism and exposure history, age, pregnancy status, liver history, blood disorders, current medicines including metronidazole, and whether household or hygiene measures are needed to prevent reinfection.
Verify whether the compounded capsule is intended to match a supported mebendazole regimen and whether longer use requires blood-count or liver monitoring.

When to refer

Severe rash, mouth sores, fever, facial swelling, jaundice, unusual bruising, seizure, or signs of serious allergy requires urgent assessment.
Uncertain diagnosis, pregnancy, age under two, prolonged or high-dose use, recurrent infection, immune suppression, or treatment failure warrants specialist review.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Mebendazole has established uses for selected intestinal worms; the approved U.S. dosage form is a chewable tablet rather than this compounded capsule.

01 / Human research

The clearest clinical signal

DailyMed labeling supports pinworm, whipworm, roundworm, and hookworm treatment, and CDC guidance emphasizes diagnosis-specific instructions and reinfection prevention.

02 / Real-world reports

What people describe

People may value a capsule format, but should understand the need for organism-specific dosing, hygiene measures, interaction review, and follow-up when symptoms persist.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Gastrointestinal effects are common. Serious skin reactions with metronidazole, liver injury, blood-count changes, allergy, seizures, pregnancy, and age require review.

Does the research match this exact product?

Partly. Ingredient and strength evidence exists, but the compounded capsule is not the approved chewable product.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Evidence brief in reviewReviewed sources are listed above

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments